Brief report · 30 Jun 2026
Conference abstractPublished 2 Nov 2015
Covalent inhibition of bacterial type I dehydroquinase – Opportunities for anti-virulence therapies
Universidad de Santiago de Compostela, Spain
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The loss of effectiveness of current antibiotics caused by the development of drug resistance, along with the evident decline in antibiotic research by the major pharmaceutical companies during the last 50 years, has triggered the search for novel antibiotics and alternative therapies. Targeting bacterial virulence is an attractive choice that is increasingly being explored. The inhibition of virulence factors will lead to a loss of the ability of bacteria to cause infection in the host and, as a consequence, they could be more easily eliminated by the immune system. A promising target for the development of new anti-virulence agents is the type I dehydroquinase enzyme (EC 4.2.1.10, aroD gene, DHQ1). This enzyme does not have any counterpart in human cells and seems to act as a virulence factor in vivo as the deletion of the aroD gene has been proven to afford satisfactory live oral vaccines. In this talk, several irreversible inhibitors of this enzyme that cause the covalent modification of the DHQ1 from Salmonella typhi and Staphylococcus aureus and that are able to reduce the ability of Salmonella enteritidis to kill A459 respiratory cells will be presented. The resolution of diverse crystal structures of DHQ1 from Salmonella typhi chemically modified by those compounds, the detection by mass spectroscopy of the reaction intermediates, in conjunction with the results of molecular dynamics simulations, allowed us to explain the inhibition mechanism of those compounds. Our recent results on this project will be presented.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Medicinal Chemistry.
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Concepción González-Bello”
